Prognostic Value of Inflammatory and Nutritional Index in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab in Second-Line Therapy

This study aims to evaluate the impact of inflammatory and nutritional index on the prognosis of patients who have experienced progression with platinum-based chemotherapies and subsequently received Nivolumab treatment for non-small cell lung cancer (NSCLC). The investigation included 124 patients who underwent treatment and observation at the medical oncology clinic from February 2022 to June 2023. A retrospective analysis was conducted on the medical records of 1144 individuals diagnosed with non-small cell lung cancer (NSCLC). After applying exclusion criteria, 124 patients were included in the study. Inflammatory and nutritional index values were calculated based on the pre-treatment blood values of the patients. Our results demonstrated a relationship between decreased SII and increased PNI ratios, indicating a connection with better overall survival. Furthermore, we established that the existence of adrenal metastasis was recognized as an independent risk factor linked to overall survival. SII and PNI variables were statistically significant in terms of the risk of death (p< 0.05). multivariate Cox regression model, having adrenal metastasis (HR: 2.61; 95%CI: 1.15-5.90; p= 0.021) increased the risk of death (p= 0.007, -2 loglikelihood= 455,371). The data underscores the predictive value of inflammatory and nutritional indices for treatment responses. These parameters, derived from routine assessments of hemoglobin, albumin, lymphocyte, neutrophil, and platelet levels, provide accessible information compared to complex and expensive methods. Subsequent multicenter studies may set a standardized cut-off value for routine use, emphasizing the necessity for broader validation through extensive research.